Sera Prognostics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.1%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.68next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Active Commercial and Medicaid Partner Programs Quarterly3.0Target: Expand partner programs to 15–17 states by year-end 2026
Payer Engagement (Number of Payers in Active Discussions) Quarterly13Target: Broad national coverage and reimbursement
Quarterly Net Loss Quarterly-8.4MTarget: Reduce base operating expenses by nearly $10 million annually starting in 2027
Watch Items
- Payer Reimbursement and Coverage DecisionsTrigger: Failure to secure contracts with major commercial or Medicaid payersAction: Re-evaluate commercial sales force allocation and focus on state-level Medicaid pilot programs.
- Cash Burn Rate and RunwayTrigger: Cash, cash equivalents, and marketable securities falling below $50 millionAction: Implement further workforce reductions or utilize the $40 million at-the-market (ATM) equity facility.
- CE Mark Dossier Submission and ApprovalTrigger: Delays in submitting or receiving CE Mark for PreTRM GlobalAction: Reallocate European commercialization preparations and focus resources on U.S. Wave 1 and Wave 2 target states.
Research as of 19 Jun 2026